Table 3

Summary of the KCS patients

Patient Eye Age Sex Primary condition Serum % Subj RB1 Fluo2 Subj 1 month RB1 1 month Fluo2 1 month Subj 2 months RB1 2 months Duration of use Side effects Other Rx at same time Other Rx previouslya
1R52FLinear IgA50488 3 weeksItch, pain and dischargeV, H
2R79FOCP1004141313512b 7 monthsAllergic to CAP H
3R52FOCP100446235242 monthH
3LOCP100412112710242 monthH
4R55FSjøgren50398 1 daySmall peripheral sterile infiltrate with overlying defect
5R73FSjøgren5041612 1 weekSwelling and rednessV, A
6R69FSjøgren5041273125382 months
7R55FSjøgren504891361 monthH, SC, SR
8R45FSJS504101427626b 3 monthsSR
9R41MSJS502652652 weeksA
9LSJS5029429112 weeksA
  • a = All patients had puncti occluded and were on 10 minute to 2 hourly hypromellose or saline (without preservative) drops and twice to four times daily ointment. b = continued drops for more than 2 months. 1 = National Eye Institute Rose Bengal scoring system (0–18). 2 = National Eye Institute Fluorescein scoring system (0–15). RB = rose bengal score, Fluo = fluorescein score, Subj = subjective score, Rx = treatment, V = viscotears, A = acetylcysteine, H = hyaluronic acid (Healon), SC = scleral contact lens, SR = silicone rubber contact lens. OCP = ocular cicatricial pemphigoid, SJS = Stevens-Johnson syndrome, CAP = chloramphenicol.

  • Patients felt worse and stopped serum drops. They were not available for review at time of discomfort while they were still on serum. At time of review a week or more later the findings were the same as the pretreatment parameters.